ReSPECT™ Clinical Trials
  • LEPTOMENINGEAL METASTASES (LM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • CONTACT US
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • RECURRENT GLIOBLASTOMA (GBM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINCIAL TRIAL
      • TRIAL INFORMATION
        • QUICK OVERVIEW
      • TRIAL GUIDE FOR PATIENTS
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • CONTACT US
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • PEDIATRIC BRAIN CANCER
    • CANCER GUIDE FOR PATIENTS- EPENDYMOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CANCER GUIDE FOR PATIENTS – HIGH GRADE GLIOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
Select Page

Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News

by Plus Therapeutics | Jun 16, 2025 | GBM

Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...

Spotlight on Leadership: Dr. Toral Patel, Principal Investigator for the RESPECT-GBM Clinical Trial

by Plus Therapeutics | Jun 10, 2025 | GBM

At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal...

Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial

by Plus Therapeutics | Jun 10, 2025 | GBM

Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...

Advancing Hope on Brain Tumor Awareness Day: Plus Therapeutics and Game On Glio Unite for Glioblastoma Patients

by Plus Therapeutics | Jun 8, 2025 | GBM

Each year, Brain Tumor Awareness Day serves as a critical reminder of the challenges faced by brain cancer patients, and the urgent need for continued research, innovation, and advocacy. At Plus Therapeutics, we are proud to stand alongside passionate individuals and...

Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation

by Plus Therapeutics | Jun 8, 2025 | GBM

Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation Today is Brain Tumor Awareness Day—a day dedicated to raising awareness for those affected by brain tumors and honoring the patients, caregivers, and advocates working...

New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner

by Plus Therapeutics | Jun 4, 2025 | GBM

New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...
« Older Entries
Next Entries »

Recent Posts

  • ReSPECT Team Supports Cancer Research at the Winship 5K During Breast Cancer Awareness Month
  • ReSPECT-LM Receives Additional $1.9 Million Advance Payment From CPRIT
  • September Is Childhood Cancer Awareness Month
  • Targeted Radiotherapies and Brain Tumor Treatment Challenges on The Bio Report Podcast
  • Plus Therapeutics CEO Highlights the Role of Precision Medicine in Cancer Treatment

Recent Comments

    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use
    • Forward Looking Statement
    • Social Media Guidelines
    • ReSPECT Blog
    Copyright © 2025 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.
    This site uses cookies to improve your experience. A cookie is a file sent to your device when you access a site. By using this site, you agree to the use of cookies on your device for tracking and analytics. Cookie SettingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT